06 · M&A, BD & licensing

M&A, BD & licensing

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 2 min read

Bookmarks need a Mind Club sign-in. How sign-in works

One licensing deal with disclosed terms, one partnership milestone and one takeover report; no acquisition announced in the window.

DealAsset or platformTerms, as statedArea
AbbVie and DISCO PharmaceuticalsResearch collaboration with an option to license AND-gated bispecific antibodies for solid tumors; targets not disclosed$40M upfront; up to $2.5B in option, development and other milestones; tiered royaltiesOncology
Evotec and Bristol Myers SquibbA second CELMoD protein degrader from their partnership; FDA accepted the IND, Phase 1 expected in 2027No financial terms in the reports we readOncology
Sanofi and Insmed (report)Bloomberg reports Sanofi is weighing a takeover bid, citing unnamed peopleNo price reported; no deal announcedRare & genetic

BioSpace (11.19) (opens another website in a new tab); PharmExec (11.19) (opens another website in a new tab); GeneOnline (11.20) (opens another website in a new tab); Pharmaceutical Technology (11.20) (opens another website in a new tab) Press. DISCO’s own release, read through Yahoo Finance (11.19) (opens another website in a new tab) Co, is timestamped 11:00 pm PT on 11.18, just before the window; we include it because the 11.19 edition did not cover it. Innogen’s license of efsubaglutide alfa to Arcera came out at 1:56 am PT on 11.19, also before the window, with no amounts disclosed.

RED TEAM

The $2.5B headline assumes every option and milestone is paid on undisclosed targets. The Insmed story rests on unnamed sources, and a deal may never be offered. Analysis